Avant Immunotherapeutics Inc - Initial Statement of Beneficial Ownership (3)
2008年3月18日 - 8:34AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Expires:
January 31, 2008
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
KELER TIBOR
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/7/2008
|
3. Issuer Name
and
Ticker or Trading Symbol
AVANT IMMUNOTHERAPEUTICS INC [AVAN]
|
(Last)
(First)
(Middle)
30 PARK ROAD
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
Sen. VP & Ch Scientific Off. /
|
(Street)
OTTSVILLE, PA 18942
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
3/7/2008
(1)
|
3/7/2018
|
Common Stock
|
254243
(1)
|
$8.16
|
D
|
|
Explanation of Responses:
|
(
1)
|
As of March 7, 2008 (the "Effective Date"), Dr. Keler Tibor beneficially owns options to purchase 254,243 shares of common stock, par value $0.001 per share (the "Shares"), of AVANT Immunotherapeutics, Inc. Options to purchase 157,093 Shares are exercisable as of the Effective Date with one twenty-fourth (1/24) of the remaining options becoming exercisable each subsequent month following the Effective Date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
KELER TIBOR
30 PARK ROAD
OTTSVILLE, PA 18942
|
|
|
Sen. VP & Ch Scientific Off.
|
|
Signatures
|
/s/ Tibor Keler
|
|
3/17/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Avant Immunotherapeutics (MM) (NASDAQ:AVAND)
過去 株価チャート
から 8 2024 まで 9 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAND)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Avant Immunotherapeutics (MM) (ナスダック市場): 0 recent articles
その他のAvant Immunotherapeutics Incニュース記事